CAS: 14611-52-0; Selegiline Hydrochloride

该化合物是选择性和不可逆转的单胺氧化酶-B(MAO-B)抑制剂,通常用于研究和制药应用,其主要优点包括MAO-B具有高度特性,最大限度地减少与MAO-A的相互作用,并减少饮食性亚胺相互作用的风险(奶酪效应),复合物具有...

结构式图片

欧盟法规

C&L通报REACH预注册

上下游产品

CAS号2323-36-6 1-[4-[2-[(4-chl... | CAS号826-10-8 ()-Methamphetam...

合成工艺路线路线简述

    📜司来吉兰 盐酸盐置于盐酸体系中,用 异丙醇 用作溶剂,化学反应 2.0H,以145 G的收率获得盐酸司来吉兰
    参考文献:一种盐酸司来吉兰的合成工艺
    标题:一种盐酸司来吉兰的合成工艺
    摘要:本发明涉及化学制药领域,具体涉及盐酸司来吉兰的制备方法.本发明方法避免了使用麻黄碱,伪麻黄碱,脱氧麻黄碱等管控品;本发明的原料廉价易得,合成路线短,生产安全环保,降低了合成成本.使用本发明制备方法,可以高收率得到高纯度的目标化合物,易于工业化的大规模生产.

    海关参考信息

    专利信息


    专利号:US-9751877-B2
    优先权日:2012-09-21
    标题 :Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders
    发明人:PETTERSSON MARTIN YOUNGJIN; JOHNSON DOUGLAS SCOTT; SUBRAMANYAM CHAKRAPANI; O'DONNELL CHRISTOPHER JOHN; AM ENDE CHRISTOPHER WILLIAM; GREEN MICHAEL ERIC; PATEL NANDINI CHATURBHAI; STIFF CORY MICHAEL; TRAN TUAN PHONG; KAUFFMAN GREGORY WAYNE; STEPAN ANTONIA FRIEDERIKE; VERHOEST PATRICK ROBERT
    权利人:PFIZER
    摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    专利号:IT-201700008702-A1
    优先权日:2017-01-26
    标题:METHOD OF SYNTHESIS OF SELEGILINA BASE

    专利号:ES-2794012-T3
    优先权日:2008-10-27
    标题 :Intermediaries for the synthesis of mTOR kinase inhibitors

    专利号:US-2006205787-A1
    优先权日:2005-01-25
    标题 :Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1,3-dione
    发明人:MULLER GEORGE W; CHEN ROGER S
    权利人:MULLER GEORGE W; CHEN ROGER S
    摘要:This invention relates to racemic and stereomerically pure 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1,3-dione, and prodrugs, salts and solvates thereof. Synthesis, methods of use, and pharmaceutical compositions of racemic and stereomerically pure 4-amino-2-(3-methyl-2,6-dioxo-piperidine-3-yl)-isoindole-1,3-dione, and prodrugs, salts and solvates thereof, are disclosed.

    专利号:US-9771379-B2
    优先权日:2015-09-24
    标题:N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]OXAZIN-8a(8H)-yl)-thiazol-4-yl) amides
    发明人:BRODNEY MICHAEL AARON; BUTLER CHRISTOPHER RYAN; ZHANG LEI; O'NEILL BRIAN THOMAS
    权利人:PFIZER
    摘要:The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, n nwherein the variables R 1 , R 2 , R 3 , R 4 and X are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    专利号:WO-2012172449-A1
    优先权日:2011-06-13
    标题:Lactams as beta secretase inhibitors
    发明人:BRODNEY MICHAEL AARON
    权利人:PFIZER; BRODNEY MICHAEL AARON
    摘要:Compound and pharmaceutically acceptable salts of the compound are disclosed, wherein the compound has the structure (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. The compound of formula I is useful as beta secretase inhibitor for use in the treatment of Alzheimer's and other neurodegenerative and/or neurological disorders.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Lees AJ. Selegiline hydrochloride and cognition. Acta Neurol Scand Suppl. 1991;136:91-4. doi: 10.1111/j.1600-0404.1991.tb05027.x. 12(2):159-174. doi: 10.4155/tde-2020-0118. Epub 2021 Feb 9. Suppl(Suppl):29-37. doi: 10.1136/jnnp.52.suppl.29.
    5: George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O'Malley SS. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry. 2003 Jan 15;53(2):136-43. doi: 10.1016/s0006-3223(02)01454-3. 17(3):199-206. doi: 10.2133/dmpk.17.199. 46(11):1037-40. 19(1):46-56. doi: 10.2174/1871524919666181126124846. 25(8):1597-613. doi: 10.1016/s0278-5846(01)00205-6. 44(3):865-77. doi: 10.3109/21691401.2014.998824. Epub 2015 Jun 4. 44(10):1613-1621. doi: 10.1080/03639045.2018.1483387. Epub 2018 Aug 20. 26(2):150-161. doi: 10.1080/1061186X.2017.1350858. Epub 2017 Jul 18. 13(10):1535-40. doi: 10.1023/a:1016035730754. 16(4):417-425. doi: 10.2174/1570163815666180418144019. 40(5):632-8. doi: 10.3109/03639045.2014.884124. Epub 2014 Feb 12. 57(1):37-42. doi: 10.1007/s002280100278.
    8:542. doi: 10.3389/fneur.2017.00542.

    合成参考文献


    摘要:Mahmood I; Clin Pharmacokinet 33 (2): 91-102 (1997)
    参考文献:10.1007/s00228-002-0469-y
    摘要:Palovaara S, Anttila M, Nyman L, Laine K. Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline. European Journal of Clinical Pharmacology. 2002 May 22;58(4):259–63. doi: 10.1007/s00228-002-0469-y.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知